Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • ALPN-101
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
    • FAQs
    • Investors Contact
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  leadership  |  documents  |  committee composition  | 

faqs  |  investors contact  | 
  • January 6, 2021
    Summary ToggleAlpine Immune Sciences Announces Executive Leadership Addition and Promotion
    Pamela Holland , Ph.D., Joins as Senior Vice President, Research Remy Durand , Ph.D., Promoted to Chief Business Officer SEATTLE --(BUSINESS WIRE)--Jan. 6, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments
    Read More
  • December 17, 2020
    Summary ToggleAlpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
    SEATTLE --(BUSINESS WIRE)--Dec. 17, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the 39th Annual J.P.
    Read More
  • December 11, 2020
    Summary ToggleAlpine Immune Sciences Appoints Natasha Hernday to Board of Directors
    SEATTLE --(BUSINESS WIRE)--Dec. 11, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A.
    Read More
  • November 24, 2020
    Summary ToggleAlpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
    SEATTLE --(BUSINESS WIRE)--Nov. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of the Alpine senior leadership team will
    Read More
  • November 16, 2020
    Summary ToggleAlpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
    SEATTLE --(BUSINESS WIRE)--Nov. 16, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate in a fireside chat at the
    Read More
  • November 12, 2020
    Summary ToggleAlpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
    - Conference call and webcast today at 4:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Nov. 12, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune / inflammatory diseases, today provided a
    Read More
  • November 5, 2020
    Summary ToggleAlpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update
    SEATTLE --(BUSINESS WIRE)--Nov. 5, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release third quarter 2020 financial
    Read More
  • October 7, 2020
    Summary ToggleHollings researchers discover new biomarker to prevent graft-versus-host disease in stem cell transplants
    Hollings researchers discover a new biomarker, plasmacytoid dendritic cells expressing the ICOS ligand, whose activity can be blocked by the dual-acting drug candidate ALPN-101 to prevent graft-versus-host disease following hematopoietic stem cell transplantation.
    Read More
  • September 15, 2020
    Summary ToggleAlpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
    SEATTLE --(BUSINESS WIRE)--Sep. 15, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the Oppenheimer Fall
    Read More
  • September 8, 2020
    Summary ToggleAlpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
    SEATTLE --(BUSINESS WIRE)--Sep. 8, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the H.C.
    Read More

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 98 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Leadership
    • Documents
    • Committee Composition
  • FAQs
  • Investors Contact